What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Immune system
His scientific interests lie mostly in Chimeric antigen receptor, Immunotherapy, Immunology, Antigen and Cell biology.
The Chimeric antigen receptor study combines topics in areas such as CD28, ErbB, Adoptive cell transfer and Interleukin 4.
His work on Cancer immunotherapy as part of general Immunotherapy study is frequently linked to Viral vector, therefore connecting diverse disciplines of science.
While the research belongs to areas of Immunology, John Maher spends his time largely on the problem of Cell, intersecting his research to questions surrounding Malignant disease.
John Maher focuses mostly in the field of Cell biology, narrowing it down to topics relating to Tumor microenvironment and, in certain cases, Signal transducing adaptor protein, Virology, Calcium flux and Mucin.
His ErbB Receptors study incorporates themes from Carcinogenesis and Cancer research.
His most cited work include:
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. (669 citations)
- Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. (300 citations)
- Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. (300 citations)
What are the main themes of his work throughout his whole career to date?
John Maher mostly deals with Chimeric antigen receptor, Cancer research, Immunotherapy, Immunology and Cancer.
The concepts of his Chimeric antigen receptor study are interwoven with issues in CD28, Adoptive cell transfer, Cancer immunotherapy and ErbB.
His work deals with themes such as Molecular biology, Integrin and Cell biology, which intersect with CD28.
His Cancer research research incorporates elements of Receptor, Car t cells, Mesothelioma and ErbB Receptors.
His work carried out in the field of Immunotherapy brings together such families of science as Cell, Tumor microenvironment, T cell, Cytokine receptor and In vivo.
His Antigen study integrates concerns from other disciplines, such as Ex vivo and T-cell receptor.
He most often published in these fields:
- Chimeric antigen receptor (85.83%)
- Cancer research (83.40%)
- Immunotherapy (74.49%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (83.40%)
- Chimeric antigen receptor (85.83%)
- Car t cells (17.41%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Chimeric antigen receptor, Car t cells, Immunotherapy and T cell.
John Maher has researched Cancer research in several fields, including Homing, MUC1, Cytotoxicity, MTT assay and External beam radiotherapy.
In the field of Chimeric antigen receptor, his study on CAR T-cell therapy overlaps with subjects such as Synergistic combination.
John Maher has included themes like Hypoxia, Cytokine release syndrome, Clinical trial and ErbB Receptors in his Car t cells study.
His research in Immunotherapy intersects with topics in Cancer cell, Head and neck cancer, Chemotherapy and ErbB.
His research in T cell is mostly focused on CD28.
Between 2018 and 2021, his most popular works were:
- CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies (40 citations)
- CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies (40 citations)
- CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies (40 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Immune system
His primary areas of study are Chimeric antigen receptor, Cancer research, Immunotherapy, Homing and T cell.
His study in Car t cells and CAR T-cell therapy falls within the category of Chimeric antigen receptor.
His Cancer research research integrates issues from In vivo and Cytotoxicity.
His studies deal with areas such as MUC1 and Monoclonal antibody as well as Immunotherapy.
His MUC1 research is multidisciplinary, incorporating perspectives in CD28, Granzyme B and Triple-negative breast cancer.
His Homing research incorporates themes from Cancer stem cell and Angiogenesis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
